Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
gptkb:Enliven_Therapeutics
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Rahul_Ballal
|
| gptkbp:developedBy |
gptkb:IMR-687
|
| gptkbp:focusesOn |
gptkb:beta-thalassemia
sickle cell disease rare genetic disorders |
| gptkbp:foundedYear |
2016
|
| gptkbp:headquartersLocation |
gptkb:Boston,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Imara Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:status |
acquired
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:IMRA
|
| gptkbp:website |
https://imaratx.com/
|
| gptkbp:bfsParent |
gptkb:Samsara_BioCapital
|
| gptkbp:bfsLayer |
6
|